



HANSA-2 (PBC 7) Implementation

Progress update in 2024

(January to Jul)

- 1.TB epidemic in Lao PDR
- 2. End TB strategy
- 3. TB program achievements
- 4. HANSA2 PBC 7: Reach the unreached to End TB
- 5. HANSA2 TB achievements
- 6. TB program activities conducted from January to Jun 2024
- 7. NTP challenges and next steps

1. TB epidemic in Lao PDR

Estimates of TB burden, 2023

Method for the estimation of incidence (2023): Extrapolated from pre-2020 trends as published in 2020 for countries with no shortfall in notifications compared with 2019

```
Total TB incidence (Number) = 10 000 (6 200-15 000)

Total TB incidence (Rate per 100 000 population) = 132 (81-197)

HIV-positive TB incidence (Number) = 470 (280-710)

HIV-positive TB incidence (Rate per 100 000 population) = 6 (4-9)

MDR/RR-TB incidence (Number) = 63 (31-95)

MDR/RR-TB incidence (Rate per 100 000 population) = 1 (0-1)
```

Method for the estimation of mortality (2023): see section "4.3 Estimating TB mortality among HIV-negative people from estimates of case fatality rates and TB incidence" in the technical appendix.


```
HIV-negative TB mortality (Number) = 680 (340-1 100)

HIV-negative TB mortality (Rate per 100 000 population) = 9 (5-15)

HIV-positive TB mortality (Number) = 76 (44-120)

HIV-positive TB mortality (Rate per 100 000 population) = 1 (1-2)
```

Source: WHO Lao PDR draft country profile 2024



2. END TB Strategy



The End TB Strategy: Vision, Targets and Pillars



Vision:

A world free of TB

Zero TB deaths, Zero TB disease, and Zero TB suffering

Goal:

End the Global TB epidemic

PILLAR 1 Integrated, patient- centered TB care and		Bold policies and supportive systems		Intensified research and innovation
prevention	XXX.		XXX.	
Government st	ewardship and	d accountability, w	rith monitoring	and evaluatio
Buildin	g a strong coa	lition with civil so	ciety and comm	nunities
Prote	cting and pron	noting human righ	nts, ethics and	equity

	MILESTONES		SDG*	END TB	
	2020	2025	2030	2035	
Reduction in number of TB deaths compared with 2015 (%)	35%	75%	90%	95%	
Reduction in TB incidence rate compared with 2015 (%)	20%	50%	80%	90%	
TB-affected families facing catastrophic cost due to TB (%)	s 0%	0%	0%	0%	






TARGETS

3. TB program achievements (2023)

Year	2020	2021	2022*	2023*
Population # (U.N.)	7.3 M	7.4M	7.5M	7.6M
TB incidence rate/100k pop.	149	143	138	133
# (WHO estimates) (a)	(11,000)	(10,582)	(10,350)	(10,108)
Notification rate/100k (new & relapse) (b)	109.8	82.7	114	120
TB treatment coverage (b/a)	74%	58%	84%	90%
Presumptive TB tested for diagnostic (new test) #	46,006	34,880	44,825	48,393
Population testing rate for TB %	0.63%	0.48%	0.60%	0.64%
Presumptive TB with GeneXpert valid test	40,878	34,254	43,866	47,128
(Xpert MTB testing coverage) %	(89%)	(98.2%)	(98%)	(97%)
Notified TB cases new and relapse #	8,013	6,123	8,686	9,124
Bacteriologically confirmed PTB new and relapse # and %	4,462 (55.7%)	4,001 (65.3%)	5,421 (62.1%)	5,625 (61.7%)
TB notified from ACF #	2,120	1,159	2,031	2,176
(%)	(27%)	(19%)	(24%)	(24.5%)
TB in children 0-4#	18	8	26	36
TB in children 5-14#	55	43	69	67
TB notified by community/CSOs #	430	270	412	419
TB notified by private sector #	193	21	25	32
TB notified in prisons # (non ACF)			171	219
Treatment success of drug sensitive TB	89.9%	88.6%	88.5%*	-
(new and relapse)	(6,087/6,770)	(7,183/8,112)	(6,732/7,610)	
TB patients with HIV test #	6,618	5,221	7,679	7,968
(% among all TB cases)	(83%)	(84.5%)	/8,776 (87.5%)	/9,095 (87.6%)
TB/HIV treatment coverage #	369/610	307/610	349/470	369/470
(% of TB/HIV estimated incidence)	(60%)	(51%)	(74%)	(78.5%)
TB/HIV patients on ARV#	300/369	257/307	254/349	287/369
(%)	(81%)	(84%)	(73%)	(78%)
New PLHIV started TPT (CHAS)	598 (60%)	560 (56%)	613 (61%)	703 (70%) 3q
Children under 5 started IPT (estimated 0.4	316/1,781	175/1,594	286/2,128	304/2,173
per household of pulmonary MTB+)	(18%)	(11%)	(13%)	(14%)
DR-TB patients enrolled #	41/49	40/44	44/52	37/42
% enrolled among diagnosed	(84%)	(90%)	(85%)	(88%)
DR-TB treatment success	30/41	33/40	31/44	
	(73%)	(82%)	(70%)	

TB treatment coverage of WHO incidence estimate (new and relapse all forms), 2005-2023 *



^{*}DHIS2 TB tracker data, 2023 preliminary data with estimated TB incidence 133/100k

4. HANSA 2 PBC 7: Reach the unreached to End TB

PBC 7: Increase TB prevention and care coverage and reaching

the unreached to End TB

PBC Condition 1:


Number of notified TB cases of all forms (New and Relapse)

PBC Condition 2:


Number of household contact children under 5-year-old received Tuberculosis

Preventive Treatment

4.1 HANSA 2 PBC 7 Condition 1: Number of notified TB cases of all forms (new and relapse)



4.2 HANSA2 PBC 7 Condition 2 Number of household contact eligible received Tuberculosis Preventive Treatment (TPT)



4.3 HANSA 2 PBC 7 activities

2.1 Training related per diems/transport/other costs

- Training province and district TB staff, HCs, VHVs, prison nurses based on updated National TB manuals on screening, diagnosis, treatment, contact investigation, M&E;
- On site coaching by MDR unit team at district/health centre level for ambulatory treatment management;
- Practical Approach on Lung Health (PAL) Course for Hospital doctors at central province and district levels for TB staff
 including OPD, IPD;
- Training of central province and district doctors on management of MDR-TB
- Training of radiologist and technicians on chest X-ray reading in province and district hospitals and prisons
- Training on GeneXpert and Lab SOPs for lab technicians
- Train HIV/AIDS workers on screening of active TB and LTBI at province and district levels (in ART and other POC)

2.3 Supervision/surveys/data collection related per diems/transport/other costs

- TB/HIV joint on site visits to selected sites (ARTs, POCs) once a quarter by NTC and CHAS
- Monitoring visits by provincial level to district and health center levels; and supervision by District level to 1000 health centres;
- Operational costs for Active case finding (ACF) in prisons, high TB burden districts;
- TB tracker on site coaching in all 162 TB units (central, provincial and district levels) for DQA;
- TB patients' home visit to screen all HHC including children (5,500 BC TB patients per year) and TPT;
- HCs staff conduct home visits to follow-up TB patients treatment and HHC children and adults receiving TPT by HC staff
- Community based TB interventions conducted by CSOs in selected districts

2.5 Transport samples of presumptive and diagnosed TB patients; 100% samples from district and health centres sent to Xpert laboratory.


4.3 HANSA 2 GF Input based activities

- Procurement of TB diagnostics (GeneXpert cartridges) and medicines (100% Y1, 80% Y2 and 60% Y3 for first line TB drugs)
- Procurement of health equipment (laboratory equipment and X-ray machines)
- Technical assistance
- Matching funds for Laboratory through NCLE


4.4 Co-financing investment and activities

- Communication material and printing for TB program
- Additional training and supervision
- Additional ACF operational costs for provinces and prisons
- Procurement of TB Medicines (first line TB drugs) and diagnostics (0% in Y1, 20% in Y2 and 40% in Y3)
- Procurement of health equipment (laboratory reagents and consumables and additional digital X-ray machines for ACF teams and high TB burden district hospitals)

5.1 HANSA 2 PBC 7.1 Number of notified TB cases of all forms (New and Relapse) January to Jul 2024



5.2 HANSA 2 PBC7.2 Number of household contact children under 5-year-old received TPT January to Jul 2024



6. TB program activities conducted from January to Jun 2024

- Achieving orders of TB drugs and diagnostic tests procurement with GF direct payment (TB drugs to arrive in country August-December 2024),
- Updating National guidelines and testing during training sessions in 5 provinces,
- Limited number of outreach ACF in remote districts,
- Updating the TB information system (TB tracker module 2) to monitor and report on TPT,
- Improving laboratory data management with NRL and NCLE,
- World TB day in Saysettha district hospital of Vientiane Capital
- Continued MDR management and culture follow-up,
- Online coaching on TPT with provinces and districts staffs,
- NTC and PTC coaching visits in selected remote districts on TPT and DQA for TB tracker

7 Gaps/Challenges/Next steps (1)

Gaps/Challenges

- ➤ Just receive funding of the HANSA1 Year 3 to implement the activities to meet PBC7 targets:
 - Suffering of transportation of specimen to GeneXpert sites
 - Limited active case finding (ACF) due to lack of operational cost funding
 - Delay of conducting activities as home visit for contact examination by health center staff

Next steps

➤ Urgent to disburse of the funds to the provinces and districts to conduct all the planned and budgeted high impact interventions to reach the PBC7 1 and 2 indicators targets including specimen transportation, outreach ACF and household contact examination, training and supportive supervision at all levels

7. Gaps/Challenges/Next steps (2)

Gaps/Challenges

- ➤ Limited integration of TB related activities with other health interventions
- ➤ Delay in data entry and need for data quality improvement; Re-training is needed for data quality improvement;

➤ Need to decentralize and maintain the GeneXpert laboratory network including in selected high TB burden districts

Next steps

- More advocacy and capacity-building local health providers at the district and health center levels.
- Continue and expand support to data entry staff by conduct refresher training, on site coaching or online to ensure the quality of data entry and real time
- ➤ DPF/NCLE and NTC/NRL to continue collaborating for management and maintenances of the GeneXpert laboratory network

#